You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Update on alopecia at hair and nails symposium

By Dermot - 23rd Mar 2020 | 17 views

Alopecia areata

The hair and nails symposium on the second day of the PCDSI conference opened with a talk from Dr Ahmed Kazmi on the topic of male and female pattern hair loss.

It was the first of two talks delivered by London-based Dr Kazmi, GP and dermatology specialty doctor, on alopecia.

The first talk provided advice to delegates on accurate diagnosis, treatment options available and on ways to develop an effective approach to the condition.

The most common form of alopecia, Dr Kazmi said, is “pattern hair loss”. Some 50 per cent of Caucasian men have the condition by the age of 50, while 50 per cent of women have pattern hair loss at the age of 80.

He highlighted the differences between scarring and non-scarring alopecia. For instance, scarring alopecia is rare and includes loss of the hair follicle with no potential for regrowth. In contrast, scarring alopecia is common, the hair follicle is present and there is usually potential for regrowth.

The condition is associated with significant psychosexual and psychosocial effects, Dr Kazmi advised, which is why holistic care is important for patients.

Patients must be advised that there is no cure (aside from hair transplantation) and healthcare professionals must ensure appropriate education and support is provided to patients, due to the psychological comorbidities associated with pattern hair loss.

Dr Kazmi recommended patients avoid using damaging hair treatments and products. He also stressed the importance of an adequate diet, particularly protein.

Doctors should avoid over-investigating the condition, but he said blood tests can be considered, as well as hormone studies, if clinically relevant.

Pattern hair loss is also associated with cardiovascular problems, which is why cholesterol and other tests associated with the heart are advised, he said.

Advice on camouflage options available, such as wigs, should be given to patients, and any coexisting scalp conditions treated.

Medications available include minoxidil foam, which helps keep hair in the androgen phase for longer.

But patients should be advised that shedding can occur in the first month of treatment and informed that the product needs to be used for up to 12 months, as response times are slow.

Minoxidil is also available in oral tablet form and is suitable for males and females. Dutasteride can also be used in males and females.

In his second talk, Dr Kazmi looked at the conditions alopecia areata (AA) and telogen effluvium and presented cases on each.

Telogen effluvium, which is commonly associated with a stressful trigger, is usually self-limiting.

While the recovery time averages about nine months, it can be much longer in some cases.

Stressful triggers can include an acute or chronic illness, accident, weight loss, surgical operation, skin disease and medications, among others.

Treatment options for telogen effluvium include minoxidil (topically or orally), diet and lifestyle advice and treating any co-existing scalp conditions, Dr Kazmi concluded.

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]